Hellerup, Denmark, February 9, 2023, – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces full-year results for the period January 1 to December 31, 2022.

2022 has been a year of great progress for UNION with several important achievements paving the way for a very exciting 2023, including positive topline results from the Phase 2b study with oral orismilast in psoriasis, advancement of our mid- to late-stage clinical programs with orismilast and niclosamide, presentations and publications of data at leading scientific conferences and in peer-reviewed journals as well as continued development of a purposeful company culture, The UNION Way, to support the growth of the organization.

Kim Kjøller, Chief Executive Officer of UNION therapeutics said:

I am very proud of the progress made in 2022 with significant advancement of our pipeline leading up to positive topline results from our Phase 2b study with oral orismilast in psoriasis, confirming the best-in-class potential of orismilast. 2022 was also the year where the enrollment target was reached for the platform study with niclosamide nasal spray tested in immunocompromised patients, and finally, but not less importantly, we have worked closely with all colleagues to define our way of working, The UNION Way.”


Morten Boesen, Chief Financial Officer of UNION therapeutics adds:

"I am pleased to announce our full-year results for 2022. The investments in our clinical programs translated into very significant advancements across the pipeline, positioning us well for important data read-outs in 2023, but also demonstrating the capital efficiency of our development-focused business model. I am also very happy with the progress of our ESG-related initiatives, ranging from broad stakeholder engagement around disease awareness to closer collaboration with suppliers around the CO2 footprint across our value chain.


Financial results for the full year 2022


Highlights for orismilast


Highlights for niclosamide


Business highlights


UNION’s Annual Report for 2022

This announcement is a summary of UNION’s Annual Report for 2022, published on February 9, 2023. A PDF version of the Annual Report will be available for download here: Annual Report 2022



Morten Boesen, Chief Financial Officer, UNION therapeutics A/S

+45 2381 5487

[email protected]


Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S

+45 5385 3044

[email protected]


About UNION therapeutics

UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology and infectious diseases, two large and fast-growing therapeutic areas. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at http://www.uniontherapeutics.com